Apollomics, Inc. (NASDAQ:APLM) Short Interest Update

Apollomics, Inc. (NASDAQ:APLM) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 2,600 shares, a decline of 58.1% from the February 28th total of 6,200 shares. Based on an average trading volume of 17,100 shares, the short-interest ratio is currently 0.2 days. Approximately 0.3% of the company’s stock are short sold.

Apollomics Stock Performance

Shares of APLM opened at $8.40 on Friday. Apollomics has a fifty-two week low of $6.20 and a fifty-two week high of $75.00. The firm’s 50-day simple moving average is $7.99 and its two-hundred day simple moving average is $10.42.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.